1. 260 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis. (12th April 2019) Authors: Marzo-Ortega, Helena; Deodhar, Atul; Miceli-Richard, Corinne; Baraliakos, Xenofon; Gladman, Dafna D; Martin, Ruvie; Safi, Jorge; Porter, Brian; Shete, Abhijit Journal: Rheumatology Issue: Volume 58(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Issue 6 (13th December 2016) Authors: Braun, Jürgen; Baraliakos, Xenofon; Deodhar, Atul; Baeten, Dominique; Sieper, Joachim; Emery, Paul; Readie, Aimee; Martin, Ruvie; Mpofu, Shephard; Richards, Hanno B Journal: Annals of the rheumatic diseases Issue: Volume 76:Issue 6(2017) Page Start: 1070 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1). Issue 12 (December 2016) Authors: Deodhar, Atul A.; Dougados, Maxime; Baeten, Dominique L.; Cheng‐Chung Wei, James; Geusens, Piet; Readie, Aimee; Richards, Hanno B.; Martin, Ruvie; Porter, Brian Journal: Arthritis & rheumatology Issue: Volume 68:Issue 12(2016) Page Start: 2901 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52‐week pooled results from two phase 3 studies. (25th May 2017) Authors: Wei, James C.‐C.; Baeten, Dominique; Sieper, Joachim; Deodhar, Atul; Bhosekar, Vaishali; Martin, Ruvie; Porter, Brian Journal: International journal of rheumatic diseases Issue: Volume 20:Number 5(2017) Page Start: 589 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. Issue 2 (21st November 2018) Authors: Braun, Jürgen; Deodhar, Atul; Landewé, Robert; Baraliakos, Xenofon; Miceli-Richard, Corinne; Sieper, Joachim; Quebe-Fehling, Erhard; Martin, Ruvie; Porter, Brian; Gandhi, Kunal K; van der Heijde, Désirée Journal: RMD open Issue: Volume 4:Issue 2(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Incidence of Uveitis in Secukinumab‐treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. Issue 5 (30th April 2020) Authors: Deodhar, Atul A.; Miceli‐Richard, Corine; Baraliakos, Xenofon; Marzo‐Ortega, Helena; Gladman, Dafna D.; Blanco, Ricardo; Das Gupta, Ayan; Martin, Ruvie; Safi, Jorge; Porter, Brian; Shete, Abhijit; Rosenbaum, James T. Journal: ACR open rheumatology Issue: Volume 2:Issue 5(2020) Page Start: 294 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials. Issue 6 (September 2021) Authors: Gottlieb, Alice B.; Mease, Philip J.; Kirkham, Bruce; Nash, Peter; Balsa, Alejandro C.; Combe, Bernard; Rech, Jürgen; Zhu, Xuan; James, David; Martin, Ruvie; Ligozio, Gregory; Abrams, Ken; Pricop, Luminita Journal: Journal of clinical rheumatology Issue: Volume 27:Issue 6(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Issue 1 (12th August 2022) Authors: Brunner, Hermine I; Foeldvari, Ivan; Alexeeva, Ekaterina; Ayaz, Nuray Aktay; Calvo Penades, Inmaculada; Kasapcopur, Ozgur; Chasnyk, Vyacheslav G; Hufnagel, Markus; Żuber, Zbigniew; Schulert, Grant; Ozen, Seza; Rakhimyanova, Adelina; Ramanan, Athimalaipet; Scott, Christiaan; Sozeri, Betul; Zholobo... Journal: Annals of the rheumatic diseases Issue: Volume 82:Issue 1(2023) Page Start: 154 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Issue 10378 (4th March 2023) Authors: Kimball, Alexa B; Jemec, Gregor B E; Alavi, Afsaneh; Reguiai, Ziad; Gottlieb, Alice B; Bechara, Falk G; Paul, Carle; Giamarellos Bourboulis, Evangelos J; Villani, Axel P; Schwinn, Andreas; Ruëff, Franziska; Pillay Ramaya, Larisha; Reich, Adam; Lobo, Ines; Sinclair, Rodney; Passeron, Thierry; Mart... Journal: Lancet Issue: Volume 401:Issue 10378(2023) Page Start: 747 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Issue 10235 (9th May 2020) Authors: McInnes, Iain B; Behrens, Frank; Mease, Philip J; Kavanaugh, Arthur; Ritchlin, Christopher; Nash, Peter; Masmitja, Jordi Gratacós; Goupille, Philippe; Korotaeva, Tatiana; Gottlieb, Alice B; Martin, Ruvie; Ding, Kevin; Pellet, Pascale; Mpofu, Shephard; Pricop, Luminita Journal: Lancet Issue: Volume 395:Issue 10235(2020) Page Start: 1496 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗